—Õ�°–òŠw
’˜�@�‘
1)
�¼Œû�HŽi: ˆã—ÖòŠw. ‘æ5”Å, –x�@—¹•½�@ŠÄ�C, Š£�@Œ«ˆê‚ç�@•Ò�W, œA�ì�‘“X (2009).
2)
�¼Œû�HŽi: ŽÀ–±ŽÀ�KŽ–‘OŠw�K‚Ì‚½‚߂̒²�ÜŠw, ŽÄ�è�³�Ÿ‚ç�@ŠÄ�C, Œú“c�Kˆê˜Y‚ç�@•Ò�W, œA�ì�‘“X (2009).
3)
�¼Œû�HŽi: ƒVƒiƒŠƒI�Ç—á‰ð�Í -ˆã—Â̌»�ê‚Å�¡�c-, �‚ŽR�@–¾�@•Ò�W, œA�ì�‘“X (2009).
˜_�@•¶
1)
Marie Nagai, Takahiro Fukamachi,
Masayuki Tsujimoto, Kenichiro Ogura, Akira Hiratsuka, Hisakazu Ohtani, Satoko
Hori, Yasufumi Sawada: Inhibitory effects of herbal extracts on the activity of
human sulfotransferase isoform sulfotransferase 1A3 (SULT1A3). Biol. Pharm. Bull., 32, 105-109
(2009).
2)
ú㌴�»Žq, ŽR�XŒ³”Ž, ’†‘º�@”C, �¼Œû�HŽi, ‰œ–ì’B�Æ, ’ƒ‰®Œ´�Ø•äŽq, ŽO–Ø�¶–ç, “c‘º�F—Y, •½ˆä‚݂ǂè, •Љª˜aŽO˜Y, ‰h“c•q”V: �H“¹‚ª‚ñ‰»Šw•úŽË�ü—Ö@‚É‚¨‚¯‚é5-ƒtƒ‹ƒIƒ�ƒEƒ‰ƒVƒ‹ŒŒŸ÷’†”Z“x‚Æ•›�ì—p‚Æ‚Ì‘ŠŠÖ. TDMŒ¤‹†, 26, 7-13 (2009).
3)
Sayo
Horibe, Kohji Takara, Tetsuya Minegaki, Noriaki Ohnishi, Teruyoshi Yokoyama: Distribution
of ABCG2 (BCRP) and ABCC2 (MRP2) mRNAs in rat small intestine and liver. EXCLI Journal, 8, 12-19 (2009).
4)
•õŠ_“N–ç,
�¬—Ñ�@–r, �V�@�NŒ›, –k“c“¿�º, �X“c‘�Žq, ‹g‰ª–r“W, ’Ò�@—²Žu, “n�@‰ë�Ž, •�“¡�r•F, �£”ö�@“O:
•ó’ËŽs—§•a‰@‚É‚¨‚¯‚é‰@“à�»�܃uƒ��[Ž�‰t‚Ì—Õ�°Žg—pŒoŒ±. ލ•@‚Æ—Õ�°, 55, 26-30 (2009).
5)
Jahye Kim, Hisakazu Ohtani, Masayuki
Tsujimoto, Yasufumi Sawada: Quantitative comparison of the convulsive activity
of combinations of twelve fluoroquinolones with five nonsteroidal anti-inflammatory
agents. Drug
Metab. Pharmacokinet., 24, 167-174 (2009).
6)
Fumiaki
Kitazawa, Toshio Abe, Kumi Ueda, Satoshi Murakami, Kohshi Nishiguchi, Kohji
Takara, Teruyoshi Yokoyama, Hikofumi Sugii: Relation of age with
myelosuppression induced by the CHOP regimen in patients with Non-Hodgkin�fs
Lymphoma. Cancer Therapy, 7, 133-140 (2009).
7)
Masayuki Tsujimoto, Maya Horie, Hiroko Honda, Kohji
Takara, Kohshi Nishiguchi: The structure-activity correlation on the inhibitory
effects of flavonoids on cytochrome P450 3A activity. Biol. Pharm. Bull., 32, 671-676 (2009).
8)
Tsutomu
Nakamura, Noboru Okamura, Mariko Yagi, Hideki Omatsu, Motohiro Yamamori, Akiko
Kuwahara, Kohshi Nishiguchi, Masanori Horinouchi, Katsuhiko Okumura, Toshiyuki
Sakaeda: Effects of ABCB1 3435C>T genotype on serum levels of cortisol and
aldosterone in women with normal menstrual cycles. Genet. Mol. Res., 8, 397-403 (2009).
9)
Kyohei
Shintaku, Satoko Hori, Masayuki Tsujimoto, Hideaki Nagata, Shoji Satoh, Kiyomi
Tsukimori, Hitoo Nakano, Tomoyuki Fujii, Yuji Taketani, Hisakazu Ohtani,
Yasufumi Sawada: Transplacental pharmacokinetics of diclofenac in perfused
human placenta. Drug Metab. Dispos., 37, 962-968 (2009).
10) Kohji Takara, Noriaki Kitada, Eri
Yoshikawa, Kazuhiro Yamamoto, Sayo Horibe, Toshiyuki Sakaeda, Kohshi
Nishiguchi, Noriaki Ohnishi, Teruyoshi Yokoyama: Molecular changes to HeLa
cells on continuous exposure to SN-38, an active metabolite of irinotecan
hydrochloride. Cancer Lett., 278, 88-96 (2009).
11) Akiko Kuwahara, Motohiro Yamamori, Kohshi
Nishiguchi, Tatsuya Okuno, Naoko Chayahara, Ikuya Miki, Takao Tamura, Tsubasa
Inokuma, Yoshiji Takemoto, Tsutomu Nakamura, Kazusaburo Kataoka, Toshiyuki
Sakaeda: Replacement of cisplatin with nedaplatin in a definitive
5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with
esophageal squamous cell carcinoma. Int.
J. Med. Sci., 6, 305-311 (2009).
12) –k“c“¿�º, �¼–ì‰ë�s, ˆÀ“c�@��, �X“c‘�Žq, “¡ˆä�ç‰ê, •õŠ_“N–ç, ‹ß“¡–œ—F”ü, ˆ¢“ì�ߎq, �‚—Ç�PŽj, “n�@‰ë�Ž: ˆê”Ê•a‰@‚É‚¨‚¯‚é“û‚ª‚ñ‰»Šw—Ö@‚̋ςĂñ‰»‚ð‚ß‚´‚µ‚Ä (‘æ2•ñ�j-FEC‚¨‚æ‚ÑTC—Ö@‚É‚¨‚¯‚éˆÀ‘S�«‚ÌŒŸ“¢-. Šà‚Ɖ»Šw—Ö@, 36, 1671-1675 (2009).
‘��@�à
1)
Toshiyuki Sakaeda, Motohiro Yamamori,
Akiko Kuwahara, Kohshi Nishiguchi: Pharmacokinetics and pharmacogenomics in
esophageal cancer chemoradiotherapy. Adv.
Drug Deliv. Rev., 61,
388-401(2009).
Šw‰ï”•\“™
�@�@�@Šw‰ï”•\
1)
“°‰º�^—œ, �¬’r”ü��, –å˜e—SŽq, ‰Ô–[‰Á“ÞŒb, ŒÜ•S‘ •�Žm, ˜a“c�@“Ö, ŠpŽR���D, ê –{”Ž—Y, �¼Œû�HŽi, •½ˆä‚݂ǂè: ˆÀ‘S‚ÈŠO—ˆ‰»Šw—Ö@‚É‚¨‚¯‚é–ò�ÜŽt‚Ì–ðŠ„‚É‚Â‚¢‚Ä, ‘æ30‰ñ“ú–{•a‰@–ò�ÜŽt‰ï�@‹ß‹EŠw�p‘å‰ï (‘å�ã), 2009. 1. 24-25.
2)
�a’J“Þ•ä, �…“c’¼”ü, �A“c‹MŽj, ‘å�¼�G–¾, ŽR‰º˜a•F, ŠpŽR���D, ê –{”Ž—Y, �¼Œû�HŽi, •½ˆä‚݂ǂè, �r�ì‘nˆê, Šâ“cŒ’‘¾˜Y: Žè�p•”ƒTƒeƒ‰ƒCƒg–ò‹Ç‚̉^—p‚ÆŽè�p’†‚Ì�R‹Û–òŽg—p•û–@‚Ì“K�³‰», ‘æ30‰ñ“ú–{•a‰@–ò�ÜŽt‰ï�@‹ß‹EŠw�p‘å‰ï (‘å�ã), 2009. 1. 24-25.
3)
�¬–ì—R‰Á—¢, �A“c‹MŽj, “c’†Œ’‘¾, ŽR�XŒ³”Ž, Šp–{в•v, ŠpŽR���D, ê –{”Ž—Y, �¼Œû�HŽi, •½ˆä‚݂ǂè: ƒ^ƒNƒ�ƒŠƒ€ƒXŒŒ’†”Z“x‘ª’è‚É‚¨‚¯‚éACMIA–@‚ÆMEIA–@‚Ì”äŠr, ‘æ30‰ñ“ú–{•a‰@–ò�ÜŽt‰ï�@‹ß‹EŠw�p‘å‰ï (‘å�ã), 2009. 1. 24-25.
4)
�A“c‹MŽj, Šp–{в•v, ŽR�XŒ³”Ž, ŠpŽR���D, ê –{”Ž—Y, �¼Œû�HŽi, •½ˆä‚݂ǂè: �tˆÚ�AгŽÒ‚É‚¨‚¯‚éƒ^ƒNƒ�ƒŠƒ€ƒX‚ƃvƒ�ƒgƒ“ƒ|ƒ“ƒv‘jŠQ�܂̖ò•¨‘ŠŒÝ�ì—p, ‘æ30‰ñ“ú–{•a‰@–ò�ÜŽt‰ï�@‹ß‹EŠw�p‘å‰ï (‘å�ã), 2009. 1. 24-25.
5)
ŠÛŽR“Þ•ä, ŠpŽR���D, Šp–{в•v, ê –{”Ž—Y, �¼Œû�HŽi, •½ˆä‚݂ǂè: ƒwƒpƒŠƒ“‹Nˆö�«ŒŒ�¬”ÂŒ¸��Ç(HIT)‚ÉŠÖ‚·‚éˆã—Ã�]Ž–ŽÒ‚Ì”Fޝ“x’²�¸, “ú–{–òŠw‰ï‘æ129”N‰ï (‹ž“s), 2009. 3. 26-28.
6)
�ã“c�C•½, �웽�´��, ‘�Œ©‹±Žq, ‘º“c�¬”Í, –؉ºŒ’Ži, ‹g“c–¾�O, Šp–{в•v, �¼Œû�HŽi, •½ˆä‚݂ǂè: ƒ�ƒ‹ƒtƒ@ƒŠƒ“ŽŠ“K“Š—^—ÊŒˆ’è‚É‚¨‚¯‚éASP-PCR–@‚ð—p‚¢‚½ˆâ“`ŽqŒ^”»’è‚Ì—L—p�«, “ú–{–òŠw‰ï‘æ129”N‰ï (‹ž“s), 2009. 3. 26-28.
7)
ŽR–{˜a�G, Œ´�@Œ«‘¾, ‰i“c�³’j, �‚—Ç�PŽj, �¼Œû�HŽi, •½ˆä‚݂ǂè, ‰¡–ì�_ˆê: ƒ‰ƒpƒ}ƒCƒVƒ“•W“Iƒ^ƒ“ƒpƒNŽ¿(mTOR)ƒVƒOƒiƒ‹“`’BŒn‚̉h—{Š´’mƒVƒXƒeƒ€‚Æ‚µ‚Ä‚Ì–ðŠ„‚Æ‚»‚Ì•ªŽqƒ�ƒJƒjƒYƒ€, “ú–{–òŠw‰ï‘æ129”N‰ï (‹ž“s), 2009. 3. 26-28.
8)
–{“c�hŽq, ’Ò–{‰ë”V, �¬�ì”ü•äŽq, ‘�“c‰À‘ãŽq, ‰ª–{ŠG—¢��, �¬–ì�¹�K, �‚—Ç�PŽj, �¼Œû�HŽi: –ò•¨‚Ì�Á‰»ŠÇ–Œ“§‰ß�«‚É‹y‚Ú‚·ŠeŽíˆù—¿Ž�‘±”˜˜I‚̉e‹¿, “ú–{–òŠw‰ï‘æ129”N‰ï (‹ž“s), 2009. 3. 26-28.
9)
’Ò–{‰ë”V: “§�ÍŠ³ŽÒ‚É‚¨‚¯‚é�tŠOƒNƒŠƒAƒ‰ƒ“ƒX‚̕ϓ®�GƒVƒ“ƒ|ƒWƒEƒ€13�u“§�͂ɂ¨‚¯‚é–ò•¨“Š—^‚Ì–â‘è“_�v�C‘æ54‰ñ“ú–{“§�͈ãŠw‰ïŠw�p�W‰ï�E‘�‰ï (‰¡•l)�C2009. 6. 5-7.
10)
‰¡“c�lŽm, ’Ò–{‰ë”V, ”µ›½‘å‰î, �´�…–ƒ—�Œb, ŽR–{�_Žj, �™–{ŽÑ—œ, ’·—F–ƒ‹KŽq, •õŠ_“N–ç, �‚—Ç�PŽj, �¼Œû�HŽi: –��«�t•s‘Sƒ‚ƒfƒ‹ƒ‰ƒbƒg‚É‚¨‚¯‚é–ò•¨ƒgƒ‰ƒ“ƒXƒ|�[ƒ^�[‚Ì‘g�D“ÁˆÙ“I‚È”Œ»•Ï“®, ˆã—ÖòŠwƒtƒH�[ƒ‰ƒ€2009�^‘æ17‰ñƒNƒŠƒjƒJƒ‹ƒtƒ@�[ƒ}ƒV�[ƒVƒ“ƒ|ƒWƒEƒ€ (‹ž“s) �C2009. 7. 11-12.
11)
–{“c�hŽq, ’Ò–{‰ë”V, ‘�“c‰À‘ãŽq, �¬�ì”ü•äŽq, ‰ª–{ŠG—¢��, �‚—Ç�PŽj, �¼Œû�HŽi: �Á‰»ŠÇ‚É‚¨‚¯‚é–ò•¨ƒgƒ‰ƒ“ƒXƒ|�[ƒ^�[‚É‹y‚Ú‚·ƒtƒ‰ƒ{ƒmƒCƒhŠÜ—Lˆù—¿‚ÌŽ�‘±”˜˜I‚̉e‹¿, ˆã—ÖòŠwƒtƒH�[ƒ‰ƒ€2009�^‘æ17‰ñƒNƒŠƒjƒJƒ‹ƒtƒ@�[ƒ}ƒV�[ƒVƒ“ƒ|ƒWƒEƒ€ (‹ž“s), 2009. 7. 11-12.
12)
‰¡“c�lŽm, ’Ò–{‰ë”V, �™–{ŽÑ—œ, ’·—F–ƒ‹KŽq, •õŠ_“N–ç, �¼Œû�HŽi: �t•s‘S�i�sˆöŽq‚Å‚ ‚éƒCƒ“ƒhƒLƒVƒ‹—°Ž_‚Ì�Á‰»ŠÇ“®‘Ԃ̉ð–¾, ‘æ3‰ñ“ú–{�t‚Æ–ò�ÜŒ¤‹†‰ïŠw�p‘å‰ï2009 (–¼ŒÃ‰®), 2009. 9. 19-20.
13)
åM“c’¼Šó, �‚—Ç�PŽj, •õŠ_“N–ç, –k“c“¿�º, ’Ò–{‰ë”V, �¼Œû�HŽi, ‰¡ŽR�Æ—R: –Ô—…“Iˆâ“`Žq”Œ»‰ð�͂Ɋî‚¢‚½�RŽîá‡�«”’‹à�ö‘ÌŠ´Žó�«ˆöŽq‚Ì’T�õ, ‘æ19‰ñ“ú–{ˆã—ÖòŠw‰ï”N‰ï (’·�è), 2009. 10. 24-25.
14)
Hiroko Honda, Masayuki Tsujimoto, Erika
Okamoto, Tetsuya Minegaki, Kohshi Nishiguchi: Effects of continuous ingestion
of grapefruit juice on the intestinal absorption of fexofenadine in mice, 24th
JSSX Annual Meeting in Kyoto, 2009. 11. 27-29.
15)
Daisuke Shima, Masayuki Tsujimoto, Shima
Hiraoka, Ayaka Miyoshi, Tetsuya Minegaki, Kohshi Nishiguchi: Mechanism for
decreased digoxin concentration by fexofenadine in hemodialysis patients, 24th
JSSX Annual Meeting in Kyoto, 2009. 11. 27-29.
�@�@�@�u‰‰“™
1)
�¼Œû�HŽi: ‹ž“s–ò‰È‘åŠwƒI�[ƒvƒ“ƒLƒƒƒ“ƒpƒX, ƒ~ƒj�u‹` (‹ž“s), 2009. 8.
2)
�¼Œû�HŽi: �_ŒË–ò‰È‘åŠw‘åŠw‰@�u‹`, ƒtƒ@�[ƒ}ƒVƒ…�[ƒeƒBƒJƒ‹ƒPƒA“Á˜_ (�_ŒË), 2009.
11.
3)
�¼Œû�HŽi, ’Ò–{‰ë”V, •õŠ_“N–ç: ‹ž“s–ò‰È‘åŠwˆê”ÊŒöŠJ�u�À, ƒ|ƒXƒ^�[Œfަ (‹ž“s), 2009. 11.
�@�@�@‚»‚Ì‘¼
1)
�¼Œû�HŽi: ŽQ‰Á. ‹ž“s–ò‰È‘åŠw�E‹ž“s•{•a‰@–ò�ÜŽt‰ï�@˜AŒgƒ��[ƒNƒVƒ‡ƒbƒv (‹ž“s), 2009. 1.
2)
�¼Œû�HŽi: ŽQ‰Á. ‹ž“s•{–ò�ÜŽt‰ï�E‹ž“s•{•a‰@–ò�ÜŽt‰ï�@ŽÀ–±ŽÀ�KŽó“ü˜A—�‰ï (‹ž“s), 2009. 8.
3)
�¼Œû�HŽi: ˆÏˆõ, ‰Û‘è�Ó”CŽÒ, ‘�Ї. ‹ž“s–ò‰È‘åŠw�@–òŠw‹¤—pŽŽŒ±OSCE (‹ž“s), 2009. 12.
4)
’Ò–{‰ë”V: ‰Û‘è�Ó”CŽÒ. ‹ž“s–ò‰È‘åŠw�@–òŠw‹¤—pŽŽŒ±OSCE (‹ž“s), 2009. 12.
5)
•õŠ_“N–ç: ƒXƒ^ƒbƒtƒ`�[ƒt. ‹ž“s–ò‰È‘åŠw�@–òŠw‹¤—pŽŽŒ±OSCE (‹ž“s), 2009. 12.
6)
�¼Œû�HŽi, ’Ò–{‰ë”V, •õŠ_“N–ç: •]‰¿ŽÒ. “¯ŽuŽÐ�—Žq‘åŠw�@–òŠw‹¤—pŽŽŒ±OSCE (‹ž“s), 2009. 12.